search icon
caba-img

Cabaletta Bio Inc, Common Stock

CABA

NSQ

$1.908

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$90.32M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
503.96K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.72
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.99 L
$13.5 H
$1.908

About Cabaletta Bio Inc, Common Stock

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCABASectorS&P500
1-Week Return7.3%1.39%1.18%
1-Month Return49.22%-4.97%6.44%
3-Month Return5.82%-11.13%-0.73%
6-Month Return-50%-10.21%-2.01%
1-Year Return-81%-6.5%12.12%
3-Year Return49.22%0.1%42.84%
5-Year Return-77.66%28.49%93.86%
10-Year Return-80.9%76.62%180.28%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue0.01----[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue354.00K733.00K3.68M1.43M-[{"date":"2020-12-31","value":9.61,"profit":true},{"date":"2021-12-31","value":19.9,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":38.71,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit0.01(733.00K)(3.68M)(1.43M)-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-7330000000,"profit":false},{"date":"2022-12-31","value":-36840000000,"profit":false},{"date":"2023-12-31","value":-14260000000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin100.00%----[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses33.83M46.31M54.14M74.66M125.14M[{"date":"2020-12-31","value":27.04,"profit":true},{"date":"2021-12-31","value":37.01,"profit":true},{"date":"2022-12-31","value":43.26,"profit":true},{"date":"2023-12-31","value":59.66,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(33.83M)(46.31M)(54.14M)(74.66M)(125.14M)[{"date":"2020-12-31","value":-3383300000,"profit":false},{"date":"2021-12-31","value":-4631300000,"profit":false},{"date":"2022-12-31","value":-5413900000,"profit":false},{"date":"2023-12-31","value":-7466000000,"profit":false},{"date":"2024-12-31","value":-12514100000,"profit":false}]
Total Non-Operating Income/Expense988.00K48.00K2.33M13.97M18.55M[{"date":"2020-12-31","value":5.32,"profit":true},{"date":"2021-12-31","value":0.26,"profit":true},{"date":"2022-12-31","value":12.55,"profit":true},{"date":"2023-12-31","value":75.29,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(33.34M)(46.29M)(52.98M)(67.67M)(115.86M)[{"date":"2020-12-31","value":-3333900000,"profit":false},{"date":"2021-12-31","value":-4628900000,"profit":false},{"date":"2022-12-31","value":-5297500000,"profit":false},{"date":"2023-12-31","value":-6767500000,"profit":false},{"date":"2024-12-31","value":-11586400000,"profit":false}]
Income Taxes(848.00K)(757.00K)(1.16M)--[{"date":"2020-12-31","value":-84800000,"profit":false},{"date":"2021-12-31","value":-75700000,"profit":false},{"date":"2022-12-31","value":-116400000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(32.49M)(45.53M)(51.81M)--[{"date":"2020-12-31","value":-3249100000,"profit":false},{"date":"2021-12-31","value":-4553200000,"profit":false},{"date":"2022-12-31","value":-5181100000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(33.34M)(46.29M)(52.98M)(67.67M)(115.86M)[{"date":"2020-12-31","value":-3333900000,"profit":false},{"date":"2021-12-31","value":-4628900000,"profit":false},{"date":"2022-12-31","value":-5297500000,"profit":false},{"date":"2023-12-31","value":-6767500000,"profit":false},{"date":"2024-12-31","value":-11586400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(32.49M)(45.53M)(51.81M)(67.67M)(115.86M)[{"date":"2020-12-31","value":-3249100000,"profit":false},{"date":"2021-12-31","value":-4553200000,"profit":false},{"date":"2022-12-31","value":-5181100000,"profit":false},{"date":"2023-12-31","value":-6767500000,"profit":false},{"date":"2024-12-31","value":-11586400000,"profit":false}]
EPS (Diluted)(1.44)(1.80)(1.81)(1.65)(2.34)[{"date":"2020-12-31","value":-144,"profit":false},{"date":"2021-12-31","value":-180,"profit":false},{"date":"2022-12-31","value":-181,"profit":false},{"date":"2023-12-31","value":-165,"profit":false},{"date":"2024-12-31","value":-234,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CABA
Cash Ratio 3.88
Current Ratio 3.96

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CABA
ROA (LTM) -41.37%
ROE (LTM) -73.85%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CABA
Debt Ratio Lower is generally better. Negative is bad. 0.26
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.74

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CABA
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.80
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Cabaletta Bio Inc share price today?

Cabaletta Bio Inc (CABA) share price today is $1.908

Can Indians buy Cabaletta Bio Inc shares?

Yes, Indians can buy shares of Cabaletta Bio Inc (CABA) on Vested. To buy Cabaletta Bio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CABA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Cabaletta Bio Inc be purchased?

Yes, you can purchase fractional shares of Cabaletta Bio Inc (CABA) via the Vested app. You can start investing in Cabaletta Bio Inc (CABA) with a minimum investment of $1.

How to invest in Cabaletta Bio Inc shares from India?

You can invest in shares of Cabaletta Bio Inc (CABA) via Vested in three simple steps:

  • Click on Sign Up or Invest in CABA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Cabaletta Bio Inc shares
What is Cabaletta Bio Inc 52-week high and low stock price?

The 52-week high price of Cabaletta Bio Inc (CABA) is $13.5. The 52-week low price of Cabaletta Bio Inc (CABA) is $0.99.

What is Cabaletta Bio Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Cabaletta Bio Inc (CABA) is 0.80

What is the Market Cap of Cabaletta Bio Inc?

The market capitalization of Cabaletta Bio Inc (CABA) is $90.32M

What is Cabaletta Bio Inc’s stock symbol?

The stock symbol (or ticker) of Cabaletta Bio Inc is CABA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top